Proteomic profiling studies of 7500 proteins further confirmed that cyclin D1 and CDK4/6 were among the few proteins significantly reduced after MS28 treatment, and the compound exhibited greater efficacy against NSCLC cells than standard CDK4/6 inhibitors (GI50 = 0.75 μM; for palbociclib: GI50 >10 μM; for BSJ-03–123: GI50 > 10 μM). Here, CDK4 is linked to non-small cell lung carcinoma.